RABIES (HEALTHY VOLUNTEERS)
Clinical trials for RABIES (HEALTHY VOLUNTEERS) explained in plain language.
Never miss a new study
Get alerted when new RABIES (HEALTHY VOLUNTEERS) trials appear
Sign up with your email to follow new studies for RABIES (HEALTHY VOLUNTEERS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New rabies vaccine schedule tested in 2,000 volunteers
⭐️ VACCINE ⭐️ CompletedThis study tested a new rabies vaccine given in different schedules after exposure. It involved 2,040 healthy people aged 10-60. The goal was to see if the vaccine triggers a strong immune response and is safe compared to a standard vaccine.
Matched conditions: RABIES (HEALTHY VOLUNTEERS)
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:12 UTC
-
New rabies vaccine shows promise in large thai trial
⭐️ VACCINE ⭐️ CompletedThis Phase 3 trial tested a new rabies vaccine called VRVg-2 in 403 healthy volunteers in Thailand. The study compared two different vaccination schedules and also looked at combining the vaccine with rabies antibodies (immunoglobulins). The goal was to see if the new vaccine pro…
Matched conditions: RABIES (HEALTHY VOLUNTEERS)
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 18:58 UTC
-
New rabies vaccine shows promise in preventing deadly infection
Prevention CompletedThis Phase 3 trial tested a new rabies vaccine (VRVg-2) in 201 healthy adults in Thailand. Participants received the vaccine along with rabies antibodies, mimicking post-exposure treatment. The study measured immune response and safety, finding that the vaccine triggered protecti…
Matched conditions: RABIES (HEALTHY VOLUNTEERS)
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 26, 2026 18:49 UTC
-
Promising new rabies vaccine passes phase 3 test
Prevention CompletedThis phase 3 trial tested a new rabies vaccine (VRVg-2) in 640 healthy adults in France. Participants received the vaccine along with rabies immune globulin, mimicking a real post-exposure scenario. The study found that VRVg-2 produced protective antibody levels as effectively as…
Matched conditions: RABIES (HEALTHY VOLUNTEERS)
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 26, 2026 17:51 UTC